The regulatory agency green-lit VAXELIS Wednesday, pharma giant Sanofi S.A. announced. The company says the drug immunizes against diptheria, tetanus, pertussis, poliomeyelitis, hepatitis B and invasive disease due to Haemophilus influenzae type B in children between 6 months and 5 years of age. Children take it in three doses.
Sanofi said the pediatric combination vaccine will be available in the United States in 2020. It was developed in a joint-venture between Sanofi and Merck.
"Sanofi and MSD are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand," Sanofi said in a statement.
Shares of Merck were down 0.86 percent in mid-day trading Wednesday.
https://www.geezgo.com/sps/51000
Join Geezgo for free. Use Geezgo's end-to-end encrypted Chat with your Closenets (friends, relatives, colleague etc) in personalized ways.>>
Post a Comment